权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition

项目 1：通过 DC 疫苗接种和 PD-1/CSF-1R 抑制来针对免疫治疗引起的耐药性

基本信息

批准号：
10673749
负责人：
Robert M Prins
金额：
$ 37.84万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-08-11 至 2027-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10673749
关键词：
Active Immunotherapy Animal Model Animals Ants Attenuated Autologous Blood Brain Brain Neoplasms CD8B1 gene CSF1R gene Cancer Vaccines Cell physiology Cells Cellular biology Chronic Clinical Clinical Trials Data Dendritic Cell Vaccine Dendritic Cells Development Funding Gene Expression Genes Glioblastoma Glioma Health Imaging technology Immigration Immune Immune Evasion Immune response ImmunoPET Immunologic Markers Immunologic Monitoring Immunotherapy Infiltration Magnetic Resonance Imaging Malignant neoplasm of brain Mediating Modeling Monoclonal Antibodies Mus Myeloid Cells Myeloid-derived suppressor cells Neoadjuvant Therapy Newly Diagnosed PD-1 blockade Patients Phase I Clinical Trials Phenotype Physiologic pulse Positron-Emission Tomography Recurrence Resistance Series T cell infiltration T cell response T-Cell Activation T-Lymphocyte Testing Therapeutic Toxic effect Translational Research Treatment outcome Tumor Immunity Tumor-Infiltrating Lymphocytes Tumor-infiltrating immune cells Vaccination Vaccines Virus Diseases anti-PD-1 anti-tumor immune response checkpoint inhibition clinically relevant dendritic cell vaccination design effective therapy first-in-human imaging biomarker imaging modality immune checkpoint blockade immune resistance immunogenicity improved outcome inflammatory milieu inhibitor innovation insight mouse model neoplasm immunotherapy neoplastic cell novel pembrolizumab pre-clinical preclinical study programmed cell death protein 1 resistance mechanism response response biomarker targeted treatment tumor tumor microenvironment vaccination strategy

项目摘要

PROJECT SUMMARY/ABSTRACT – Project 1 The lack of effective treatments for glioblastoma (GBM) patients remains a significant health problem and highlights the need for novel and innovative approaches. Immunotherapy is an appealing strategy because of the potential ability for immune cells to traffic to and destroy infiltrating tumor cells in the brain. For the past 15 years, our group and others have been testing active vaccination strategies, such as dendritic cells (DC) pulsed with tumor lysate, to induce antitumor immunity in glioblastoma patients. From the interim results of the clinical trial we initiated in our current SPORE funding period, we found that in addition to inducing T-cell infiltration into brain tumors, DC vaccination + anti-PD1 blockade may also create a pro-inflammatory environment within the tumor that induces the immigration of immunosuppressive myeloid cells (TIM). These cells are phenotypically similar to the myeloid cells that dominantly attenuate the T-cell response to chronic viral infections, and may counteract the effective anti-tumor T-cell responses induced by DC vaccination within the tumor microenvironment. Therapies that target myeloid cells within the tumor microenvironment represent a promising new strategy. As such, inhibition of these myeloid cells using a CSF-1R inhibitor, in conjunction with autologous tumor lysate-pulsed DC vaccination (ATL-DC) and PD-1 mAb blockade, resulted in significantly prolonged survival in tumor-bearing animals with large, well-established intracranial (i.c.) gliomas. Our hypothesis is that myeloid cells mediate adaptive immune resistance in response to T cell activation induced by immunotherapy. In this SPORE Project renewal, we have planned a series of novel pre-clinical studies to re- polarize myeloid cells, to optimize how the timing and sequence of immunotherapy can influence ant-tumor immunity, and a new clinical trial to test the first-in-human combination of a new brain penetrant CSF-1R inhibitor (CSF-1Ri; PLX3397, Daiichi-Sankyo) with DC vaccination and PD-1 mAb blockade (Pembrolizumab, Merck) in patients with newly diagnosed GBM. A better understanding of the biology of these cellular interactions will provide insight into more effective ways to induce therapeutic anti-tumor immune responses for this deadly type of brain tumor. These studies span the continuum of translational research in brain tumor immunotherapy, and will likely provided informative new insights for the development of new, rational immune-based strategies for brain tumor patients.

专题摘要/摘要-专题一